A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

End Stage Renal Disease Clinical Trial

Official title:

A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01238796
• Other study ID #: 9809-CL-1407
• Status: Completed
• Phase: Phase 1
• Start date: December 2010
• Est. completion date: February 2011

Study information

• Verified date: January 2019
• Source: Cumberland Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of renal function on the biological activity of telavancin using blood samples obtained from subjects with normal renal function, severe renal impairment, and end stage renal disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: February 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Weighs at least 45 kg and body mass index of 18 to 40 kg/m2, inclusive

• An estimated creatinine clearance value based on Cockcroft-Gault method of:

• >80 mL/min for subjects with normal renal function

• <30 mL/min for subjects with severe renal impairment

• receiving hemodialysis three times a week for subjects with end stage renal impairment

• If female, the subject is at least 2 years postmenopausal, surgically sterile or practicing effective birth control, and is not pregnant or lactating

• Good venous access

Exclusion Criteria:

• History of any clinically significant acute illness (other than renal disease and conditions related to the renal disease in renal impairment subjects, such as stable diabetes or hypertension)

• Has had a kidney transplant that is still functioning

• History of unexplained syncope, cardiac arrest, unexplained cardiac arrythmia or torsade de pointes, structural heart disease, prolonged QT interval, or family history of long QT syndrome

• Known hypersensitivity to telavancin or any of the excipients in the formulation, or a history of severe allergic or anaphylactic reactions

• History of consuming more than 7 units of alcoholic beverages per week, or history of alcoholism or substance abuse within past 2 years

• Known to be positive for human immunodeficiency virus antibody

• For subjects with normal renal function, has had treatment with prescription or non-prescription drugs, including complementary and alternative medicines or over-the counter medications, with the exception of oral contraceptives, hormone replacement therapy, daily aspirin, and occasional use of acetaminophen within the past 14 days

• For subjects with renal impairment, has not been on a stable dose of concomitant medications for at least 2 weeks prior to study start or is taking any medication that would interfere with the evaluation of televancin in this study

• Has received an experimental agent within 30 days or ten half-lives, whichever is longer, prior to study drug administration

• Has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to admission

Related Conditions & MeSH terms

• End Stage Renal Disease
• Kidney Diseases
• Kidney Failure, Chronic

Intervention

Drug:
• telavancin
Intravenous

Locations

Country	Name	City	State
United States	New Orleans Center for Clinical Research	Knoxville	Tennessee
United States	Clinical Pharmacology of Miami	Miami	Florida
United States	DaVita Clinical Research	Minneapolis	Minnesota
United States	Orlando Clinical Research Center	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Cumberland Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of telavancin as estimated by antibiotic potency bioassay		Days 1-4
Primary	Concentration of telavancin as determined by standard Liquid Chromatography Tandem Mass Spectrometer (LC/MS/MS)		Days 1-4
Secondary	Pharmacokinetic variables through analysis of blood samples		Days 1-4